We are pleased to announce the availability of the DeepChek® Assay Whole Genome SARS-CoV-2 Genotyping and the DeepChek® CoV2 Software. Both combined, it offers an innovative end-to-end solution (for Research Use Only (RUO)) for SARS-CoV-2 whole genome sequencing and analysis: from SARS-CoV-2 whole-genome amplification, library preparation, high-throughput sequencing (Next Generation Sequencing, (NGS)) to genotyping and downstream software analysis with publicly available knowledge reference databases. The solution lists mutations, insertions and deletions to then identify circulating SARS-CoV-2 variants (VOCs) using RNA extracted from patients already diagnosed positive to SARS-CoV-2.
In continuation of the NGS sequencing, the software suite allows an advanced bioinformatic analysis of the raw sequencing data before the analysis and the reporting of latest epidemiological and clinical knowledge linked to the identified mutations, insertions and deletions (i.e., determination of the risk of infectivity or vaccine escape).
The DeepChek® Assay Whole Genome SARS-CoV-2 Genotyping combined with the DeepChek® CoV2 Software allow laboratories performing PCR and next generation sequencing to sequence the entire genome of the SARS-CoV-2. It is an additional technique to qPCR which generates information necessary to better control and understand the emergence of variants in general and more specifically on the main circulating variants of concern with their mutations of interest (i.e. the Spike E484K, N501Y…).
The whole-genome sequencing is to be used only in second intention on SARS-CoV-2 samples already diagnosed positive by an approved RT-PCR or RT-LAMP device.
For more information please contact us at the following email address: